Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug
Former U.S. Senator Ben Sasse has reported a significant reduction in his pancreatic tumor size after participating in a clinical trial for an experimental drug called daraxonrasib. Initially diagnosed with stage 4 pancreatic cancer, Sasse experienced a 76% decrease in tumor volume over four months of treatment. The drug targets a key growth mechanism in cancer cells, potentially extending the lives of patients who do not respond to standard chemotherapy.
- ▪Ben Sasse was diagnosed with metastatic pancreatic cancer in December 2025.
- ▪He entered a clinical trial for daraxonrasib after being given three to four months to live.
- ▪Patients treated with daraxonrasib lived a median of 13 months compared to six months for those on chemotherapy.
Opening excerpt (first ~120 words) tap to expand
Cancer News Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug Former senator calls experimental drug daraxonrasib a ‘miracle’ medication By Melissa Rudy Fox News Published April 28, 2026 7:00am EDT | Updated April 28, 2026 7:03am EDT Facebook Twitter Threads Flipboard Comments Print Email Add Fox News on Google close Video Former Sen. Ben Sasse vows to fight after stage 4 pancreatic cancer diagnosis Dr. Nicole Saphier discusses former Sen. Ben Sasse’s, R-Neb., stage 4 pancreatic cancer diagnosis, new immunotherapy advances and what to know as flu season ramps up. NEWYou can now listen to Fox News articles! Months after revealing his stage 4 cancer diagnosis, former U.S. Sen.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Fox News.
Discussion
0 commentsMore from Fox News
